Skip to main content
. 2021 Jan 29;538:192–203. doi: 10.1016/j.bbrc.2020.10.012

Fig. 2.

Fig. 2

The distribution of IGHV gene usage of RBD-targeting neutralizing antibodies. A total of 280 antibodies reported in 19 studies are analyzed [[5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [20], [21], [22], [23], [24]].